REGENXBIO Inc (RGNX) オプション

RGNX, under $8

RGNX under $10

36M share trading float.

RGNX

AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.

https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp

I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!

is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/

Strong buy @ 50!!!!

RGNX buy 66.90























normal chart




log chart

Hope no more form 4s for insider selling

Let’s see how tomorrow will be

Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?

$45 soon! Yummy

RGNX bullish 14.39



normal chart


log chart

Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.

Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.

RGNX no bid support, too early still, listed VC...